ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

Year in Review: Cutting Edge Advances in Kidney Cancer - Imaging and…

Ketan Badani

Updates in the Treatment and Management of Bladder Cancer

Integrity CE

M. Galsky, B. Guercio

Treatment (De)Intensification in RCC

International Urology Cancer Summit - IUCS

S. Kumar Pal

Review of Bladder Cancer Updates From ESMO 2024

The View on GU | with Lalani & Wallis

A. A. Lalani, C. Wallis

Urologic Oncology: What to Look for in 2025

GWU Urology

Year in Review 2024 - Bladder Cancer

Oncology 2024 Year in Review

G. Sonpavde

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Year in Review 2024 - Renal Cell Carcinoma

Oncology 2024 Year in Review

N. Mar

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Ph…

Dana-Farber Cancer Institute

B. McGregor

Year in Review: Bladder Cancer - 2024 Insights and Exciting Prospect…

Jason Hafron

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

The Surgeon's Management of Advanced Kidney Cancer

Daniel Shapiro